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INTRODUCTION
Infection with Mycobacterium tuberculosis (M. tb) causes tu-
berculosis (TB), which remains a serious global health problem, 
with an estimated incidence of 10.4 million cases per year.1 Early 
diagnosis and successful treatment have prevented millions of 
people from TB deaths each year. However, TB remains the 
leading infectious cause of death worldwide, accounting for 
about 1.3 million deaths among HIV-negative people in 2016.1 
Once individuals are infected with M. tb, approximately 5% 
develop active TB diseases, while 95% remain healthy without 
any clinical manifestation of TB.2 However, individuals with 
latent TB infection (LTBI) have a 5–15% lifetime risk of devel-
oping active TB.1 Therefore, it is imperative to screen and treat 
those with LTBI in order to effectively control TB by decreasing 
the number of active cases. 
The absence of a gold standard for identifying LTBI remains a 
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Purpose: This study aimed to evaluate ichromaTM IGRA-TB, a novel point-of-care platform for assaying IFN-γ release, and to com-
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Materials and Methods: We recruited 60 healthy subjects, and blood samples were obtained in QFT-GIT blood collection tubes. 
The blood collection tubes were incubated at 37ºC, and culture supernatant was harvested after 18–24 hours. IFN-γ responses 
were assessed by the ichromaTM IGRA-TB cartridge and the QFT-GIT IFN-γ enzyme-linked immunosorbent assay. Three active 
TB patients were recruited as a positive control for M. tb infection.
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(95.2%, κ=0.91, p<0.001), and a very strong positive correlation was observed between the IFN-γ values of both tests (r=0.91, 
p<0.001). 
Conclusion: The diagnostic accuracy demonstrated in this study indicates that the ichromaTM IGRA-TB test could be used as a 
rapid diagnostic method for detecting latent TB infection. It may be particularly beneficial in resource-limited places that require 
cost-effective laboratory diagnostics.
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challenge although two tests are widely used for this purpose: a 
tuberculin skin test (TST) and the IFN-γ release assay (IGRA). 
TST, a traditional method for detecting LTBI, measures the size 
of skin induration after an intradermal injection of 0.1 mL tu-
berculin (purified protein derivative; PPD).2 It is simple and 
economical, but false positives are frequently reported in in-
dividuals with recent BCG vaccination or exposure to nontu-
berculous mycobacteria.2 To overcome the disadvantages of 
TST, an IGRA, more specifically the QuantiFERON-TB Gold 
In-Tube (QFT-GIT) test, was developed to differentiate LTBI 
by assessing the amount of IFN-γ induced by M. tb-specific 
antigens, including ESAT-6, CFP-10, and TB7.7.3 The IGRA has 
been reported to have higher specificity and sensitivity for de-
tecting LTBI than TST. However, its utility is restricted in low- 
and middle-income countries with limited resources, and as 
such, TST continues to be recommended for diagnosis of LTBI 
by World Health Organization (WHO) guidelines.4
The global need for a rapid, accurate, and inexpensive point-
of-care test (POCT) has led to efforts to improve current TB di-
agnostics, including the development of Xpert MTB/RIF.1,5 A 
sensitivity and specificity greater than 90% were observed with 
the lateral flow POCT, which detects antibodies to epitopes of 
M. tb cell wall proteins in TB patients,6 and a serological POCT 
using the microchip-based TB enzyme-linked immunosorbent 
assay (ELISA) had better sensitivity than sputum smear mi-
croscopy (72% vs. 56%).7 Another POCT determines M. tb li-
poarabinomannan with 55.6% sensitivity and 100% specificity 
in patients with both TB and HIV.8 Unlike active TB diagnos-
tics, the diagnostic tests for LTBI are not able to detect M. tb it-
self, but rather mostly rely on assessing adaptive immune re-
sponses against M. tb antigens. A novel skin test, C-Tb, uses 
recombinant ESAT-6 and CFP-10 antigens instead of the PPD 
antigen, and it is not affected by BCG vaccination.9 It showed 
a similar safety profile to the traditional TST.9 A POC molecu-
lar test that measures IFN-γ or IP-10 mRNA has been reported 
as well.10,11 However, limited accuracy and lack of international 
standards remain primary challenges to developing a POCT.12 
In South Korea, TB is still a major infectious disease, with an 
estimated incidence of 77 cases per 100000 people in 2016.13 
Most cases of TB are reported as pulmonary TB, and 68% of 
cases were bacteriologically confirmed.13 More than 70% of 
TB patients had Beijing genotypes in clinical isolates, and the 
Beijing/K strain was identified as the predominant strain dur-
ing school outbreaks.14,15 The treatment success rate was 84% 
in 2015, but new and recurrent cases are still noted, despite an 
overall decline in prevalence.13 In addition, approximately one 
third of the Korean population is at risk of developing TB due 
to LTBI and TB outbreaks, which often lead to an elevated num-
ber of individuals with LTBI. In order to avoid potential progres-
sion to active TB, a national program for preventive treatment 
of LTBI has not only targeted high risk groups, but also enact-
ed strategies to eliminate and control TB through early diag-
nosis and treatment since 2017. A nationwide test for LTBI has 
been performed in high school students, and it has been an 
obligatory requirement for workers in medical and educa-
tional facilities and for army conscription. Anyone who has a 
positive response to PPD by TST has their LTBI status con-
firmed by a second QFT-GIT test before initiating treatment 
for LTBI. 
In this study, we aimed to assess the IFN-γ performance of 
the POC ichromaTM IGRA-TB cartridge, which was developed 
by Boditech Med Inc. in South Korea. We determined IFN-γ 
responses in whole blood samples, which were incubated with 
M. tb-specific antigens. We used the same QFT-GIT test anti-
gen tubes and measured the IFN-γ responses using two differ-
ent assays: QFT-GIT IFN-γ ELISA and the ichromaTM IGRA-TB 
test. We analyzed rates of IFN-γ positive responses in each as-
say, and evaluated the diagnostic value of the test using the 
POC ichromaTM IGRA-TB cartridge. In addition, the feasibility 
of the ichromaTM IGRA-TB cartridge for identifying LTBI was 
evaluated by the total concordance of positive and negative 
IFN-γ responses between the two tests and by the association of 
quantitative values of IFN-γ released.
MATERIALS AND METHODS
Enrollment of study participants
From April to September 2017, a total of 60 normal, healthy 
subjects, including 10 recent TB contacts (≥18 years of age) with 
no clinical symptoms of active TB, were enrolled at Hallym 
University Hospital. Three active pulmonary TB patients who 
were diagnosed by clinical and radiological features and by 
microbiological identification of M. tb, were also recruited at 
the same hospital during the study period as a positive control 
of M. tb infection. Subjects who had prior history of TB were 
excluded, as were those who had HIV, cancer, or diabetes. The 
study protocol was explained to the 63 subjects, and informed 
written consent was obtained for clinical examinations and 
blood sampling for immunological testing. Ethical permission 
for this study was granted by the Hallym University Hospital 
Ethics Review Committee (IRB number 2017-27).
Preparation of blood samples
Heparinized blood samples were collected in three QFT-GIT 
blood collection tubes (QuantiFERON-TB Gold In-Tube; Qia-
gen, Hilden, Germany) and incubated upright at 37°C for 18–
24 hours. Harvested plasma was divided into two aliquots and 
stored at -70°C until the end of subject recruitment. 
QFT-GIT tests
IFN-γ ELISAs were performed with harvested plasma accord-
ing to the manufacturer’s protocol (Qiagen). Briefly, 50 μL of 
freshly prepared enzyme-conjugate solution was added to the 
wells of the microplates. IFN-γ standards were reconstituted 
based on the protocol, and 50 μL of standards and harvested 
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plasma samples were loaded into the 96-well microplates. 
The microplates were incubated at room temperature for two 
hours after mixing the conjugate and standard plasma sam-
ples. The microplates were washed six times using the diluted 
wash buffer, and 100 μL of enzyme substrate solution was add-
ed to each well. Following a 30-minute incubation at room 
temperature, 50 μL of enzyme stopping solution was added, 
and the optical density of each well was measured at 450 nm.
ichromaTM IGRA-TB tests
The ichromaTM IGRA-TB test was performed according to the 
manufacturer’s protocol (Boditech Med Inc.). Briefly, detection 
buffer was prepared by adding 150 μL of diluent into the dried 
detection buffer containing anti IFN-γ and anti-chicken IgY, 
which were both fluorescently labeled. After confirming com-
plete dissolution of the detection buffer, it was mixed with 100 
μL of culture supernatants, which were harvested from the 
QFT-GIT antigen tubes. Then, 75 μL of the mixture was loaded 
onto the nitrocellulose membrane in a cartridge. After incu-
bation at room temperature for 15 minutes, the cartridge was 
scanned, and fluorescence intensity was measured at 613 nm 
using the ichromaTM II reader (Boditech Med Inc.).
Statistical analysis
An optimal cut-off point for positive IFN-γ responses in the 
ichromaTM IGRA-TB test was selected based on the Youden’s 
index.16 The diagnostic accuracy of the ichromaTM IGRA-TB test 
was evaluated by the value of the area under the receiver oper-
ating characteristic curve (AUC) using GraphPad Prism 6 
(GraphPad Software Inc., La Jolla, CA, USA). Agreement of 
positive and negative results between the ichromaTM IGRA-TB 
and QFT-GIT tests was examined using Kappa statistics, and 
the association between IFN-γ values measured by the two 
tests was analyzed by Spearman’s rank correlation coefficient, 
using Stata 13 (StataCorp LP., College Station, TX, USA). 
RESULTS
Characteristics of the study participants 
The healthy subjects included 10 TB contacts who did not ex-
hibit any clinical symptoms. Among the 60 enrolled subjects, 
there were 50 females and 10 males, and the mean age was 42 
years (range, 22–61). The three active pulmonary TB patients 
(two males and one female) were enrolled during the same 
period. None of the three patients had sputum samples that 
were positive for acid-fast bacillus (AFB) staining, but the pres-
ence of M. tb was confirmed by culture in two of the patients 
and by polymerase chain reaction (PCR) in one patient. All 
study subjects received BCG vaccinations at a young age, and 
no subjects had a history of TB prior to enrollment (Table 1). 
Determination of M. tb infection using QFT-GIT IFN-γ 
ELISA and its POC platform 
Based on the outcomes of commercially used diagnostic QFT-
GIT tests, 32 normal, healthy subjects were confirmed to have 
LTBI. Positive IFN-γ responses were observed in 53.3% of 
healthy subjects (n=32), while 28 subjects (46.7%) showed 
negative IFN-γ responses to the QFT-GIT antigens including 
ESAT-6, CFP-10, and TB7.7 (Table 2). The QFT-GIT also detected 
positive IFN-γ responses in two TB patients whose M. tb growth 
was confirmed by culture. However, it was not able to detect 
M. tb infection in another patient who was diagnosed with M. 
tb by PCR.
Meanwhile, the IFN-γ values determined by the POC plat-
form, the ichromaTM IGRA-TB cartridge, were relatively lower 
than those measured by QFT-GIT. The calculated cut-off value 
for IFN-γ positivity was >0.21 IU/mL with a sensitivity of 91.2% 
[95% confidence interval (CI), 76.3–98.1%] and 100% specific-
ity (95% CI, 88.1–100%) in the ichromaTM IGRA-TB test (p< 
0.001). Based on the cut-off point, the ichromaTM IGRA-TB car-
tridge identified 29 subjects as having LTBI (48.3%) among the 
60 healthy subjects (Table 2). The rate of positivity was slightly 
lower with the ichromaTM IGRA-TB test than with the QFT-GIT 
test (48.3% vs. 53.3%, respectively), although the difference 
was not statistically significant (p>0.05). Among the 32 posi-
tive IFN-γ responders, as determined by the QFT-GIT test, five 
subjects showed weak positive IFN-γ responses (<1.0 IU/mL). 
Among the five weak positive responders, three subjects were 
responsible for the difference in the rates of positivity between 
the two tests, as the weak positive IFN-γ values (below 1.0 IU/
mL) in the QFT-GIT test were not sufficient for positivity with 
the ichromaTM IGRA-TB cartridge (Table 3). All other positive 
IFN-γ responders with values above 1.0 IU/mL on the QFT-GIT 
IFN-γ ELISA also exhibited positive results with the ichromaTM 
Table 1. Characteristics of the Study Participants
Healthy subjects (n=60) TB patients (n=3)
Mean age (range) 42 (22–61) 58 (46–69)
Male/Female 10/50 2/1
BCG vaccination 60 3
Prior TB history 0 0
AFB smear positive - 0
M. tb culture positive - 2
M. tb positive by PCR - 1
Drug resistant TB - 1
TB, tuberculosis; AFB, acid-fast bacillus; PCR, polymerase chain reaction.
Table 2. Percent Positivity and Percent Negativity by QFT-GIT and ichro-
maTM IGRA-TB Tests in Healthy Subjects
         Assay type % positivity (n) % negativity (n)
  QFT-GIT IFN-γ ELISA 53.3 (32) 46.7 (28)
  ichromaTM IGRA-TB 48.3 (29) 51.7 (31)
QFT-GIT, QuantiFERON-TB Gold In-Tube; ELISA, enzyme-linked immunosor-
bent assay; IGRA, IFN-γ release assay; TB, tuberculosis.
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IGRA-TB test (data not shown). Although the median IFN-γ 
response value was significantly lower in the ichromaTM IGRA-
TB test than in the QFT-GIT IFN-γ ELISA (0.18 vs. 0.66 IU/mL, 
p<0.001), there was no significant difference in the rates of 
IFN-γ positivity between the two assays (p>0.05). Positive IFN-γ 
responders, as determined by the QFT-GIT IFN-γ ELISA, also 
showed positive responses with the ichromaTM IGRA-TB test, 
except for the three individuals who had weak positivity (IFN-γ 
<1.0 IU/mL). 
We investigated the statistical significance of diagnostic ac-
curacy for the ichromaTM IGRA-TB test by analyses of agree-
ment and Spearman’s rank correlation coefficient in all 63 
study subjects. This was performed to determine if it is feasible 
to replace the commercial IGRA test with the ichromaTM IG-
RA-TB test. Our data showed excellent agreement in the total 
concordance of positivity and negativity between the two tests 
(95.2%, κ=0.91, p<0.001). The individual IFN-γ response val-
ues between the two assays did not perfectly match, however, 
there was a very strong positive correlation between the IFN-γ 
values of the two tests (r=0.91, p<0.001) (Fig. 2). The diagnostic 
accuracy of the ichromaTM IGRA-TB test suggests that it may be 
useful to identify LTBI in clinical settings.
DISCUSSION
In this study, we assessed the feasibility of the newly devel-
oped ichromaTM IGRA-TB POC platform for diagnosis of LTBI 
in healthy subjects and in TB patients. The ichromaTM IGRA-TB 
test exhibited diagnostic value in identifying M. tb infection, 
and the assay procedure was much simpler with a small car-
tridge and faster than QFT-GIT IFN-γ ELISA (total incubation 
IGRA-TB test. In three TB patients, the ichromaTM IGRA-TB 
cartridge also detected positive IFN-γ responses in two cul-
ture-confirmed patients. However, neither test was able to de-
tect M. tb infection in another patient who was diagnosed 
with M. tb by PCR.
Diagnostic value of the ichromaTM IGRA-TB test 
To examine the diagnostic value of the ichromaTM IGRA-TB 
test, AUC was measured in all 63 study participants, including 
both healthy subjects and TB patients. The AUC value of the 
test was 0.9706 (95% CI, 0.92–1.00, p<0.001), indicating the 
usefulness of the ichromaTM IGRA-TB test in differentiating 
the individuals who are infected with M. tb from non-infected 
healthy controls (Fig. 1).
Comparative analyses between the two tests for 
detecting M. tb infection 
The overall pattern of IFN-γ responses was similar between 
the two tests, although the QFT-GIT test showed higher re-
sponses with greater individual variance than the ichromaTM 
Fig. 2. Association of IFN-γ release between two different assays. The as-
sociation of the IFN-γ responses between the QFT-GIT and ichromaTM IG-
RA-TB tests was analyzed by Spearman’s correlation coefficient. The 
graph shows a very strong positive correlation of IFN-γ values between 
the two tests (r=0.91, p<0.001). QFT-GIT, QuantiFERON-TB Gold In-Tube; 
IGRA, IFN-γ release assay; TB, tuberculosis.
Fig. 1. Diagnostic value of the ichroma™ IGRA-TB test in identifying M. tb 
infection. The IFN-γ responses measured by ichromaTM IGRA-TB car-
tridges distinguished infected individuals with an AUC of 0.9706 (95% CI, 
0.92–1.00, p<0.001) in ROC curve analysis (p<0.001). IGRA, IFN-γ release 
assay; TB, tuberculosis; CI, confidence interval; AUC, area under the 
curve; ROC, receiver operating characteristic.
Table 3. Subjects Who Showed Differences in IFN-γ Positivity between 
the QFT-GIT and ichromaTM IGRA-TB Tests
Sample
QFT-GIT ELISA ichromaTM IGRA-TB cartridge
Result IFN-γ (IU/mL) Result IFN-γ (IU/mL)
1 Positive 0.42 Negative 0.16
2 Positive 0.57 Negative -0.22
3 Positive 0.95 Negative 0.12
QFT-GIT, QuantiFERON-TB Gold In-Tube; ELISA, enzyme-linked immunosorbent 
assay; IGRA, IFN-γ release assay; TB, tuberculosis.
The three positive IFN-γ responders on the QFT-GIT test were weakly positive 
(≥0.35 but <1.0 IU/mL), and those responders did not show positive responses 
on the test with the ichromaTM IGRA-TB cartridge (≤0.21 IU/mL).
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time: 15 minutes vs. 150 minutes). The test performance was 
evaluated by assessing concordance of differences between the 
tests,17 and comparative analysis revealed excellent agreement 
and a very strong positive correlation in IFN-γ performance. 
The quantitative IFN-γ response values measured by the 
ichromaTM IGRA-TB cartridge were relatively lower than those 
measured by the QFT-GIT test. However, the individual re-
sponses of positivity and negativity were well matched between 
the two tests, with the exception of three subjects who showed 
weak positive responses below 1.0 IU/mL by the QFT-GIT test. 
In this study, all differences in positivity between the two tests 
were observed near cut-off points below 1.0 IU/mL. The three 
individuals showed negative IFN-γ responses with the ichro-
maTM IGRA-TB cartridge in contrast to the QFT-GIT IFN-γ ELI-
SA (0.42–0.97 IU/mL). Several lines of evidence showed vari-
ability in diagnostic outcomes near the cut-off point in QFT-
GIT tests, and retesting has been recommended for subjects 
whose IFN-γ values are in a borderline range (0.20–0.99 IU/
mL).18,19 A recent study in South Africa has shown that both 
conversions and reversions in IGRA test responses can be de-
tected, and such repeated testing has also suggested that the 
current cut-off for IGRA-positivity in the QFT-GIT test may be 
too low.20 Raising the cut-off value to >1.0 IU/mL in confirma-
tory serial QFT-GIT tests reduced the percentage of false posi-
tives in healthcare workers in low-incidence settings.21 These 
reports indicate that weak positive responses below 1.0 IU/mL 
by the QFT-GIT test may cause an error in interpretation of the 
outcome, which necessitates further testing to confirm false 
positive or true negative responses. In this study, we could re-
test the initial outcomes in three of the five subjects with weak 
positivity (<1.0 IU/mL) by the QFT-GIT, and observed that the 
positive IFN-γ responses (0.66 and 0.42 IU/mL) were changed 
to negative results (0.13 and 0.11 IU/mL, respectively) in two 
of the subjects. This tells us that the outcome of the QFT-GIT 
test at below 1.0 IU/mL is unstable to determine positive pre-
dictive values, which might cause a discrepancy in positivity 
between the two tests in our study. A cut-off point for LTBI by 
the current QFT-GIT test should be adjusted in future studies.
South Korea is an upper middle-income country with an in-
termediate TB burden, and screening for LTBI has primarily 
been performed in high-risk groups, including close TB con-
tacts, students, military personnel, and immunosuppressed 
patients, based on the TST and QFT-GIT test. The IGRA is con-
sidered a better indicator for identifying LTBI than the TST in 
South Korea, where BCG vaccination is mandatory in infancy. 
A prospective study performed from 2004 to 2005 suggests a 
higher specificity of the IGRA for identifying LTBI, compared 
with the TST.22 Approximately 51% of individuals without risk 
of M. tb infection showed positive responses to the TST (>10 
mm induration cutoff), whereas 4% of healthy subjects were 
positive by IGRA. For recent contacts, positive responses were 
observed in 60–71% by the TST, while fewer subjects (10–44%) 
were IGRA positive. Another study, carried out from 2010 to 
2014, showed that the QFT-GIT test was superior to the TST at 
ages younger than 30, although neither the TST nor the QFT-
GIT could differentiate LTBI between healthy controls and 
contacts due to the high prevalence of LTBI.23 A higher sensi-
tivity of the IGRA was also found in immunocompromised pa-
tients, compared with the TST,24 and no significant changes in 
IFN-γ release were observed in children.25 These reports suggest 
the usefulness of an IGRA for those with impaired immune sys-
tems, as well as for healthy subjects with LTBI, in South Korea. 
One challenging issue for developing TB diagnostics in re-
source-limited settings is convenience with reduced infra-
structure and technical skills. The ichromaTM IGRA-TB used in 
this study is a new diagnostic POC platform that contains a set 
of detection antibodies, buffer, a small cartridge containing a 
nitrocellulose membrane, and a mobile instrument for read-
ing (ichromaTM II). The incubation time for samples and detec-
tion antibodies is 15 minutes, and the test may be completed 
within a total of 20 minutes. It is therefore less time-consuming 
compared to the QFT-GIT IFN-γ ELISA, and a professional ex-
pert or fully equipped laboratory is not required for the test. 
Moreover, data from our study demonstrated the diagnostic 
accuracy for the ichromaTM IGRA-TB based on comparison with 
the commercially used QFT-GIT test. Excluding the three indi-
viduals with weak positivity by the QFT-GIT test, the ichromaTM 
IGRA-TB and QFT-GIT tests showed 100% agreement in posi-
tivity and negativity rates based on the same interpretation of 
the outcome. These findings suggest that ichromaTM IGRA-TB 
may be a feasible POCT for identifying LTBI and might aid in 
TST interpretation in areas that lack clinical and laboratory ma-
terials.
Our study limitation is that there were a few patients identi-
fied at diagnosis during our study period although we focused 
on testing TB latency in healthy controls, including those with 
known TB contact. Thus, additional comparative studies con-
sidering the state of M. tb infection (latent vs. active, culture 
confirmed TB vs. non-TB) will be followed by a long-term study 
with a larger sample size. Although the excellent agreement of 
the results was proven between the alternative tests, the sensi-
tivity and specificity of the ichromaTM IGRA-TB should be fur-
ther confirmed by its own cut-off value in a cohort including 
positive and negative controls of M. tb infection. 
In conclusion, the strong correlation and agreement in IFN-γ 
performance between the ichromaTM IGRA-TB and QFT-GIT 
tests suggest that the ichromaTM POC platform could be a prom-
ising application of the IGRA in clinical settings. In particular, 
the ichromaTM IGRA-TB is advantageous over the QFT-GIT for 
its speed, convenience, and cost-effectiveness. Therefore, it 
may be reasonably used for LTBI diagnostics as a confirmatory 
test for TSTs in regions where laboratory supplies are restricted. 
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